A lower UCK1 expression for myelodysplastic syndrome (MDS) patients has been associated with reduced survival rate, while point mutations in UCK2 have been found in human leukemic cell lines made resistant to Aza-CR [20, 21]. Here, UCK2 is linked to myelodysplastic syndrome.